Emcure says Gennova is working on backward integration of its mRNA COVID-19 vaccine

Emcure says Gennova is working on backward integration of its mRNA COVID-19 vaccine The Phase I clinical trial should begin anytime soon. The animal toxicity and safety studies that was conducted as part of preclinical studies have produced desired results, says Vikas Thapar; company looking for foreign tie ups in due course

No comments:

Post a Comment